Hainan Huitong Biomedical Technology Co., Ltd

Primary objective: To evaluate the non-inferiority of the clinical efficacy of flurbiprofen gel patch in the treatment of knee osteoarthritis using the original drug Zepolas® as the positive control drug; to evaluate the superiority of flurbiprofen gel patch in the treatment of knee osteoarthritis using placebo as the control; Secondary objective: To evaluate the safety of flurbiprofen gel patch in patients with knee osteoarthritis.

Main objective: The fasting trial adopted a single-center, randomized, open, single-dose, four-period completely repeated crossover design, and the postprandial trial adopted a single-center, randomized, open, single-dose, two-period crossover design to compare the differences in absorption degree and speed between the carbidopa-levodopa sustained-release tablets (specifications: each tablet contains 50 mg carbidopa and 200 mg levodopa) produced by Hunan Jiudian Pharmaceutical Co., Ltd. and the carbidopa-levodopa sustained-release tablets (specifications: each tablet contains 50 mg carbidopa and 200 mg levodopa; trade name: Sinemet®/Xining®) certified by MSD Pharma (Singapore) Pte. Ltd. in healthy people. Secondary objective: To evaluate the safety and tolerability of carbidopa-levodopa sustained-release tablets (specifications: each tablet contains 50 mg carbidopa and 200 mg levodopa) produced by Hunan Jiudian Pharmaceutical Co., Ltd. and carbidopa-levodopa sustained-release tablets (specifications: each tablet contains 50 mg carbidopa and 200 mg levodopa; trade name: Sinemet®) certified by MSD Pharma (Singapore) Pte. Ltd. under fasting and postprandial conditions.